Hesco obtains drug registration certificate for hydrochloric acid Praxo slow release

On November 30, Hesco announced that the hydrochloric acid Praxo reprieve tablet developed by Hesco Pharmaceutical Co., Ltd., a wholly owned subsidiary of Sichuan Haisco Pharmaceutical Co., Ltd., has received the Drug Registration Certificate issued by the State Drug Administration.
specific situation is as follows: Drug name: hydrochloric acid Praxo slow release tablets acceptance number: CYHS1800082 countries, CYHS1800083 countries Certificate number: 2020S00753, 2 020S00754 Drug approval number: National Drug Code H20203600, National Pharmaceutical Code H20203601 Dosage Form: Tablet Specification: According to C10H17N3S 2 HCl-H2O meter (1) 0.375mg, (2) 1.5mg Application: Drug Registration (Domestic Production) Registration Classification: Chemicals 4 Types of Adaptive Disorders: This product is used to treat adult idiopathic Parkinson's disease Signs and symptoms, i.e. throughout the course of the disease, including the later stages of the disease, when the efficacy of L-Doba gradually weakens or changes and fluctuations (end-of-dose phenomenon or "switch" fluctuations), can be applied alone (no L-Doba) or in association with L-Doba.
Listing License Holder: Hesco Pharmaceuticals (Meishan) Co., Ltd. Praxo is a new generation of non-omegae dopamine-like polypamine-like agents with high bio-utilization, rapid drug efficacy, food-free effects, and good results for Parkinson's patients with combined depression.
the drug was approved by the FDA in 1997 for the treatment of primary Parkinson's disease (PD).
can be used at all stages of PD, can be used alone in early PD, or as an auxiliary therapy in association with lon doba therapy for advanced PD.
is currently the first-line drug recommended by PD guidelines at home and abroad.
inquiries, the hydrochloric acid Praxo tablets (taken once a day) were first listed in the European Union in 2009, then in the United States in 2010 and in Japan in 2011.
August 2014, the original research manufacturer Grigg Ingham Company's hydrochloric acid Prakso slow release film was approved for domestic import and listing, the specifications are 0.375mg, 0.75mg, 1.5mg, 3mg and 4.5mg.
July and October 2020, Zhejiang Jingxin Pharmaceutical Co., Ltd. and Jiangsu Hengrui Pharmaceutical Co., Ltd. were approved for domestic listing, respectively, with specifications of 0.75mg and 0.375mg.
is the 3rd of the same breed, as if through the consistency evaluation, of which 1.5 mg specification is the first imitation.
2019, Praxo's sales at public hospitals and county-level public hospital terminals in China exceeded 750 million yuan, including nearly 100 million yuan for Praxo's slow-release tablets, according to Mina.com.
2019 global sales of nearly $600 million, including nearly $300 million, according to IMS.
source: Hesco Enterprise Announcement